| Filed On | Filing |
|---|---|
| 16 Nov 2026 |
8-K: Results of Operations and Financial Condition
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: |
| 30 Oct 2026 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. |
| 14 Aug 2026 |
8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation
Favorable pre-clinical data reported for NMRA-215 with plan to submit IND in fourth quarter of 2026 and initiate Phase 1 study by end of 2026 |
| 27 Jul 2026 |
8-K: Other Events
Company plans to submit an IND in the fourth quarter of 2026 and to initiate Phase 1 study by the end of 2026 |
| 15 Jun 2026 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +3 more
Navacaprant did not achieve the primary endpoint in KOASTAL-2 or -3; Company to discontinue development of navacaprant |
| 29 May 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On May 27, 2026, Neumora Therapeutics, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders voted on four proposals, each of which is described in more det... |
| 07 May 2026 |
8-K: Results of Operations and Financial Condition
KOASTAL-2 and -3 studies evaluating navacaprant in major depressive disorder on track for joint topline readout in the second quarter of 2026 |
| 30 Mar 2026 |
8-K: Results of Operations and Financial Condition
New data for NMRA-511 supports unsurpassed clinical effect in a pre-specified population comparable to Rexulti and Auvelity pivotal studies |
| 11 Feb 2026 |
8-K: Regulation FD Disclosure
Important Disclosures This presentation contains forward-looking statements about Neumora Therapeutics, Inc. (the “Company,” “we,” “us,” or “our”) within the meaning of the federal securities laws, including statements related to: Neumor... |
| 12 Jan 2026 |
8-K: Regulation FD Disclosure
January 2026 Redefining Neuroscience Drug Development Exhibit 99.1 |
| 05 Jan 2026 |
8-K: Other Events
NMRA-511 demonstrated a 15.7 reduction on mean CMAI total score, representing a clinically meaningful effect |
| 21 Nov 2025 |
8-K: Unregistered Sales of Equity Securities
As previously reported, on May 9, 2025, Neumora Therapeutics, Inc. (the “Company”) entered into a Loan and Security Agreement with K2 HealthVentures LLC (“K2HV”) as the lender and the other parties thereto, as amended by that certain Fir... |
| 06 Nov 2025 |
8-K: Results of Operations and Financial Condition
Announced class-leading data from diet-induced obesity (DIO) mouse model with NMRA-215, a potentially best-in-class, highly brain-penetrant, oral NLRP3 inhibitor, and expect to initiate Phase 1 study in first quarter of 2026 |
| 27 Oct 2025 |
8-K: Other Events
NMRA-898 is structurally distinct from NMRA-861 and is the second M4 PAM in Neumora’s M4 franchise; both programs have potential best-in-class pharmacology |
| 27 Oct 2025 |
8-K: Other Events
Neumora Therapeutics Announces Class-Leading Weight Loss Demonstrated with NMRA-215 in Preclinical Diet-Induced Obesity Model |
| 06 Aug 2025 |
8-K: Results of Operations and Financial Condition
Initiated Phase 1 single-ascending dose/multiple-ascending dose (SAD/MAD) study with M4 positive allosteric modulator (PAM) NMRA-861, with data expected in the first quarter of 2026 |
| 30 May 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On May 28, 2025, Neumora Therapeutics, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders voted on four proposals, each of which is described in more det... |
| 16 May 2025 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. |
| 12 May 2025 |
8-K: Results of Operations and Financial Condition
On track to report topline data from NMRA-511 in Alzheimer’s disease agitation around the end of 2025 |
| 03 Mar 2025 |
8-K: Results of Operations and Financial Condition
KOASTAL-2 and -3 studies optimized based on learnings from KOASTAL-1; topline data expected from |
Loading...